INTERNATIONAL SESSION
Global View of Value Based Medicine - Hemisfair Ballroom 2&3 - 3rd Level
Moderator: Peggy Porter, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Health system responses to women's cancers in the Americas: Closing divides to achieve universal health coverage
Felicia M. Knaul, PhD
University of Miami
Miami, FL 

The challenge of definition and adoption; perspective from the Middle East
Sana Al Sukhun, MD, MSc
Jordanian Oncology Society
Amman, JORDAN

Breast imaging in resource constrained regions: Lessons from Uganda
Constance D. Lehman, MD, PhD
Massachusetts General Hospital
Boston, MA

Drug target discovery: how to go about it?
Markus Warmuth, MD
H3 Biomedicine
Cambridge, MA

Bench-based approaches to discover mechanisms of drug resistance (i.e. CRISPR, genome library screens, etc.)
Nikhil Wagle, MD
Dana-Farber Cancer Institute
Boston, MA

Genomics & bioinformatics (big data) in breast cancer research
Mia Levy, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

Single cell genomics and tumor heterogeneity
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Novel statistical clinical trial designs
Yu Shyr, PhD
Vanderbilt Ingram Cancer Center
Nashville, TN

Incorporating biomarkers in clinical trials
Edith Perez, MD
Genentech
South San Francisco, CA

What about neoadjuvant trials and path CR
Hope Rugo, MD
University of California
San Francisco, CA

Regulatory issues
Tatiana M. Prowell, MD
FDA/Johns Hopkins
Silver Spring, MD

EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1&2, 3&4 and Hemisfair Ballroom 2&3 - 3rd Level

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

Shifting Paradigms in Radiation Oncology – Hemisfair Ballroom 2&3 - 3rd Level
Moderator: Richard L. Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

Accelerated partial breast irradiation: Update of an ASTRO consensus guideline
Candace R. Correa, MD
Community Cancer Center
Normal, IL

Guidelines for postmastectomy radiotherapy
Abram Recht, MD, FASTRO, FASCO
Beth Israel Deaconess Medical Center
Boston, MA                                   

Advanced technologies to optimize outcomes and minimize toxicities
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Changing Recommendations for Intermediate Risk Lesions – Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

The pathology of high risk proliferative lesions of the breast
Kalliopi P. Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Clinical management of women with increased breast cancer risk based on histologic lesions
Amy C. Degnim, MD
Mayo Clinic
Rochester, MN

Managing increased breast cancer risk based on high and moderate penetrance gene mutations
Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Beyond Expression Profiling: RNA Epigenetics – Stars at Night Ballroom 3&4 - 3rd Level
Moderator: Douglas Yee, MD
University of Minnesota
Minneapolis, MN

Drugging protein synthesis in cancer therapy
Robert J. Schneider, PhD
New York University
New York, NY

Targeting RNA splicing in cancer therapy
Stephan Vagner, PhD
Institut Curie-Centre de Recherche
Orsay, FRANCE

Progress, paradigms, and pathways of long non-coding RNAs in cancer
Liuqing Yang, PhD
UT MD Anderson Cancer Center
Houston, TX

2:45 pm - 4:15 pm

Medical Treatment of HER2+++ Breast Cancer – Hemisfair Ballroom 2&3 - 3rd Level
Moderator: Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY

HER2 testing - 2017 guidelines for HER2 testing
Robert B. Jenkins, MD, PhD
Mayo Clinic
Rochester, MN

Adjuvant therapy for HER2-positive breast cancers: Is less more?
Ruth M. O'Regan, MD
University of Wisconsin
Madison, WI

Can we improve treatment tailoring in advanced HER2+ breast cancer?
Martine J. Piccart, MD, PhD
Institut Jules Bordet
Brussels, BELGIUM

Multi-Level Influences on Breast Cancer Disparities – Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Melissa L. Bondy, PhD
Baylor College of Medicine
Houston, TX

Place as a cause of breast cancer disparities in Appalachia
Electra D. Paskett, BS, MSPH, PhD
Ohio State University
Columbus, OH

Biologic, cultural and health systems influences on breast cancer disparities in Latinas
Amelie G. Ramirez, DrPH
UT Health San Antonio
San Antonio, TX

Biologic and health system determinants of breast cancer disparities in African Americans
Katherine E. Reeder-Hayes, MD
University of North Carolina
Chapel Hill, NC

Panel Discussion

The Breast Tumor Microenvironment: A Target for Therapy – Stars at Night Ballroom 3&4 - 3rd Level
Moderator: Leisha A. Emens, MD, PhD
Johns Hopkins University
Baltimore, MD

How tumor metabolism contributes to the immunosuppressive microenvironment
Jeffrey C. Rathmell, PhD
Vanderbilt University
Nashville, TN

Do tumors overcome immune surveillance by blocking dendritic cell development
David G. DeNardo, PhD
Washington University School of Medicine
St. Louis, MO

Opportunities for immune therapy and prevention
Robert H. Vonderheide, MD, DPhil
University of Pennsylvania
Philadelphia, PA

4:30 pm - 6:00 pm

Management Controversies in Locoregional Recurrence - Hemisfair Ballroom 2&3 - 3rd Level
Moderator: Irene Wapnir, MD
Stanford Women's Cancer Center
Stanford, CA

Challenges in the management of locoregional recurrence
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Local regional recurrence
Richard C. Zellars, MD
Indiana University
Indianapolis, IN

Should all patients with locoregional recurrence receive systemic therapy?
William J. Gradishar, MD
Northwestern University
Chicago, IL

Circulating Tumor Cells and Liquid Biopsies, Translation to Clinical Practice – Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Liquid biopsies in breast cancer - challenges and opportunities
Sarah-Jane Dawson, MBBS (Hons), FRACP, PhD (Cantab)
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

Exosome analysis in breast cancer: Clinical translation
Jacqueline F. Bromberg, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Circulating complexes of stromal and tumor cells in breast cancer metastasis
Dorraya El-Ashry, PhD
University of Minnesota
Minneapolis, MN

Androgen, Progesterone and Glucocorticoid Receptors: Drivers of Breast Tumor Progression or Reprogramming of Steroid Receptors During Breast Tumor Progression - Stars at Night Ballroom 3&4 - 3rd Level
Moderator: Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

Androgen receptor in breast cancer.  When might it serve as a suitable target?
Jennifer K. Richer, PhD
University of Colorado
Aurora, CO

Tracking progesterone receptor actions in breast cancer progression: Jekyll and Hyde
Carol A. Lange, PhD
University of Minnesota
Minneapolis, MN

Modulating glucocorticoid receptor function in breast cancer
Suzanne D. Conzen, MD
University of Chicago
Chicago, IL               

REGISTRATION - Main Lobby

WELCOME AND OPENING REMARKS - Hall 3
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

PLENARY LECTURE 1 - Hall 3

Potential of Radiation Therapy to Convert the Tumor into an In Situ Vaccine
Silvia C. Formenti, MD
Weill Cornell Medicine
New York, NY

GENERAL SESSION 1 - Hall 3

WILLIAM L. MCGUIRE MEMORIAL LECTURE – Hall 3
The Early Breast Cancer Trialists' Collaborative Group
Sir Richard Peto, FRS
University of Oxford
Oxford, UNITED KINGDOM

BREAK

CLINICAL SCIENCE FORUM - Stars at Night Ballroom 1&2 - 3rd Level
Controversies in the Adjuvant Treatment of ER+ Breast Cancer
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Adjuvant endocrine therapy for premenopausal ER+ breast cancer
Prudence A. Francis, MBBS, B Med Sc, FRACP, MD
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

Searching for the optimal duration of adjuvant endocrine therapy in breast cancer
Vered Stearns, MD
Johns Hopkins University
Baltimore, MD

BASIC SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level
Targeting the Tumor Immune Microenvironment
Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Epigenetic therapy activates type 1 interferon signaling to reduce immunosuppression and tumor burden
Cynthia A. Zahnow, PhD
Johns Hopkins University
Baltimore, MD

Myeloid-derived suppressor cells: many facets of regulation of tumor progression
Dmitry I. Gabrilovich, MD, PhD
The Wistar Institute
Philadelphia, PA

Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancer
Jos Jonkers, PhD
Netherlands Cancer Institute
Amsterdam, NETHERLANDS

A novel human derived organoid platform for breast cancer research
Oded Kopper, PhD
Hubrecht Institute
Utrecht, NETHERLANDS

Breast cancer patient-derived xenografts as models for metastatic progression and therapeutic response
Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

SUSAN G. KOMEN^® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES - Hall 3

SUSAN G. KOMEN^® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
The Development of Synthetic Lethal Treatments for Cancer
Alan Ashworth, PhD, FRS
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

SUSAN G. KOMEN^® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH  
Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications
Dennis J. Slamon, MD, PhD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

GENERAL SESSION 2 - Hall 3

POSTER SESSION 1 & Reception - Hall 1 

REGISTRATION - Main Lobby

POSTER SESSION 2 & continental breakfast - Hall 1

PLENARY LECTURE 2 - Hall 3
Advances in the Understanding of Mutational Signatures in Human Cells
Serena Nik-Zainal, MD, PhD
The Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

GENERAL SESSION 3 - Hall 3

CASE DISCUSSION 1 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

BASIC SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level
Mechanisms of Early Dissemination, Dormancy and Metastasis
Moderator: Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY

Oncogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY

The perivascular niche protects dormant disseminated tumor cells from therapy
Cyrus M. Ghajar, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Targeting DNA repair deficiency in triple negative breast cancers (TNBC) with G-quadruplex stabilisers
Samuel Aparicio, PhD
The University of British Columbia
Vancouver, CANADA

New clinical approaches for TNBC
Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

GENERAL SESSION 4 - Hall 3

POSTER SESSION 3 & Reception - Hall 1

REGISTRATION - Main Lobby

POSTER SESSION 4 & continental breakfast - Hall 1

PLENARY LECTURE 3 - Hall 3
Individualizing Management of the Axillary Nodes
Tari A. King, MD
Dana-Farber Cancer Institute
Boston, MA

GENERAL SESSION 5 - Hall 3

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH FUNDED BY SUSAN G. KOMEN^® - Hall 3
Tackling Breast Cancer Diversity
Nicholas C. Turner, PhD, FRCP, BM, MA
Institute of Cancer Research and Royal Marsden
London, UNITED KINGDOM

BREAK

CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

BASIC SCIENCE FORUM 3 – Stars at Night Ballroom 3&4 - 3rd Level
Intratumoral Heterogeneity: Clinical Implications from Basic Science
Moderator: Elaine R. Mardis, PhD
Nationwide Children's Hospital
Columbus, OH

Manifestations and implications of subclonal alterations in metastatic breast cancer
Sarat Chandarlapaty, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Breast cancer intra-tumor heterogeneity and its clinical implications
Charles Perou, PhD
The University Of North Carolina At Chapel Hill
Chapel Hill, NC

Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Houston, TX

Fabrice André, MD, PhD
Institut Gustave Roussy
Villejuif, FRANCE

MINI-SYMPOSIUM 2 - Hall 3

Lobular Breast Cancer - Is it a Different Disease?
Moderator: Otto Metzger, MD
Dana-Farber Cancer Institute
Boston, MA

Pathology and genomics of lobular breast carcinomas and their precursors
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Understanding the unique biology of ILC
Steffi Oesterreich, PhD
University of Pittsburgh
Pittsburgh, PA

Tailoring systemic therapy for patients with lobular breast cancer
Marco A. Colleoni, MD
European Institute of Oncology
Milano, ITALY

GENERAL SESSION 6 - Hall 3

POSTER SESSION 5 & Reception - Hall 1 

SPECIAL SESSION
View from the Trenches: What Will You Do On Monday Morning? - Stars at Night Ballroom 3&4 - 3rd Level
Moderator: Lisa A. Carey, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Panel Members:

Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Patricia Spears, BS
University of North Carolina
Chapel Hill, NC

Steven E. Vogl, MD
Montefiore Medical Center
Bronx, NY

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Registration - Main Lobby

The Year in Review - Hall 3

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Basic science
Ramon Parsons, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Translational research
Nicholas C. Turner, PHD, FRCP, BM, MA
Institute of Cancer Research and Royal Marsden
London, UNITED KINGDOM

Early breast cancer in review
Antonio C. Wolff, MD, FACP, FASCO
Johns Hopkins University
Baltimore, MD

Advanced and metastatic breast cancer
Nancy Lin, MD
Dana-Farber Cancer Institute
Boston, MA